Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
VX1 Stock Chart & Stats
€398.00
€4.45(1.12%)
At close: 4:00 PM EST
€398.00
€4.45(1.12%)
Day’s Range― - ―
52-Week Range€312.65 - €478.10
Previous CloseN/A
Volume2.00
Average Volume (3M)122.00
Market Cap
€102.81B
Enterprise Value€118.62B
Total Cash (Recent Filing)€6.61B
Total Debt (Recent Filing)€3.88B
Price to Earnings (P/E)29.5
Beta0.38
Next Earnings
May 06, 2026EPS Estimate
3.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.27
Shares Outstanding254,034,200
10 Day Avg. Volume106
30 Day Avg. Volume122
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.21
Price to Sales (P/S)9.60
P/FCF Ratio36.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€463.98Price Target Upside16.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering25
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DataStrong interim Phase 3 data for povetacicept showing meaningful efficacy and a favorable safety profile would materially reduce uncertainty and likely act as a major upside catalyst for the stock.
Commercial ExpansionRobust early adoption and payer coverage for new launches and strong uptake of pathway‑targeting therapies validate market demand outside cystic fibrosis and support revenue diversification potential.
Financial PositionA strong cash balance with no debt provides flexibility to fund late‑stage programs and launches, supporting valuation resilience while pivotal assets advance.
Bears Say
Competitive LandscapeA crowded market for B‑cell and APRIL/BAFF targeted therapies, including high‑potency competitors, could limit market share and pricing for povetacicept and other renal assets.
Profitability And CostsPlanned sales‑force expansion and increased investment across multiple late‑stage programs raise operating expense and cost‑of‑goods guidance, pressuring near‑term profitability and earnings.
Valuation And Binary Readout RiskStock valuation appears to assume clinical success while reliance on a pending pivotal povetacicept readout creates binary downside risk if interim results fall short of expectations.
Vertex Pharmaceuticals News
VX1 FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was €312.65 and its highest was €478.10 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is €102.81B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is May 06, 2026 which is in 76 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Feb 12, 2026. The company reported €4.265 earnings per share for the quarter, missing the consensus estimate of €4.334 by -€0.069.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 3.75.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 254,034,200 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of €4.265 in its last earnings report, missing expectations of €4.334. Following the earnings report the stock price went up 7.182%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:VX1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vertex Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€463.98 (16.58% Upside)
€463.98 (16.58% Upside)
Blogger Sentiment
Bullish
DE:VX1 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 94%
Bearish news 6%
Bearish news 6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.24%
12-Months-Change
Fundamentals
Return on Equity
22.54%
Trailing 12-Months
Asset Growth
13.22%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VX1 Company Deck
VX1 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive picture: strong top-line growth (Q4 +10%, FY +9%), strong margins and profitability (Q4 net income +24%, EPS +26%), a solid cash position, active capital returns, and multiple important commercial launches (CF next-gen, KASJEVY, Genavix) plus rapid advancement of a diversified pipeline (notably an emerging renal franchise with regulatory progress for povitacept). Near-term headwinds include a $200M Russia decline, gross-to-net effects from patient support programs impacting Genavix revenue, timing variability for cell therapy infusions, and increased operating investments and a higher expected tax rate in 2026. Key clinical/regulatory readouts (RAINIER, AMPLITUDE, other pivotal data) represent binary events that could materially affect future prospects. Overall, the positives (diversified growth, strong financials, multiple product and regulatory milestones) outweigh the near-term operational and timing challenges.View all DE:VX1 earnings summariesVX1 Revenue Breakdown
85.93% TRIKAFTA/KAFTRIO
6.98% ALYFTREK
6.83% Other product revenues
0.26% Other revenues
VX1 Stock 12 Month Forecast
Average Price Target
€463.98
▲(16.58% Upside)
Technical Analysis
Options Prices
Currently, No data available
---